Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation

Objective To investigate the effect and safety of iron chelation therapy on hematopoiesis in hematological malignancy patients with iron overload after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods The clinical data of 38 hematological malignancy patients who suffered from...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	ZENG Cong, CHEN Xu, HUA Juan, CHENG Tingting, MA Xia, XU Yajing
Formato:	article
Lenguaje:	ZH
Publicado:	Editorial Office of Journal of Third Military Medical University 2021
Materias:	allogeneic hematopoietic stem cell transplantation iron chelation therapy hematopoiesis Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/aff6134d7f3e4637b48cc93cef7c13a5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aff6134d7f3e4637b48cc93cef7c13a5
record_format	dspace
spelling	oai:doaj.org-article:aff6134d7f3e4637b48cc93cef7c13a52021-11-12T04:37:50ZIron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation10.16016/j.1000-5404.2021081121000-5404https://doaj.org/article/aff6134d7f3e4637b48cc93cef7c13a52021-11-01T00:00:00Zhttp://aammt.tmmu.edu.cn/Upload/rhtml/202108112.htmhttps://doaj.org/toc/1000-5404Objective To investigate the effect and safety of iron chelation therapy on hematopoiesis in hematological malignancy patients with iron overload after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods The clinical data of 38 hematological malignancy patients who suffered from iron overload after allo-HSCT and were treated in our hospital from May 2019 to June 2021 were retrospectively reviewed and analyzed. According to receiving iron chelation or not, they were divided into treatment group (n=21, oral administration of deferasirox) and control group (n=17, no iron chelation). The changes of hemoglobin (Hb) level, platelet (PLT) count, white blood cell (WBC) count and serum ferritin (SF) level were compared between the 2 groups, and the adverse reactions during administration were observed as well. Results At 2, 4 and 8 weeks after treatment, Hb level and PLT count in the treatment group were significantly improved from baseline as compared with the control group (P < 0.05), but the WBC count showed no significant difference between the 2 groups (P > 0.05). SF levels in the treatment group was decreased from baseline at 4 and 8 weeks, significantly lower than those of the control group [-867 (-1 918~ 477) vs 436 (-408~467) μg/L, P < 0.001;-1 243 (-2 784~364) vs 541 (-674~578) μg/L, P < 0.001]. None of the patients in the treatment group developed serious gastrointestinal symptoms or severe damage to liver and kidney functions. Conclusion Iron chelation therapy can effectively improve the hematopoiesis, with satisfactory safety, in the patients suffering from iron overload after allo-HSCT.ZENG CongCHEN XuHUA JuanCHENG TingtingMA XiaXU YajingEditorial Office of Journal of Third Military Medical Universityarticleallogeneic hematopoietic stem cell transplantationiron chelation therapyhematopoiesisMedicine (General)R5-920ZHDi-san junyi daxue xuebao, Vol 43, Iss 21, Pp 2302-2306 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	allogeneic hematopoietic stem cell transplantation iron chelation therapy hematopoiesis Medicine (General) R5-920
spellingShingle	allogeneic hematopoietic stem cell transplantation iron chelation therapy hematopoiesis Medicine (General) R5-920 ZENG Cong CHEN Xu HUA Juan CHENG Tingting MA Xia XU Yajing Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation
description	Objective To investigate the effect and safety of iron chelation therapy on hematopoiesis in hematological malignancy patients with iron overload after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods The clinical data of 38 hematological malignancy patients who suffered from iron overload after allo-HSCT and were treated in our hospital from May 2019 to June 2021 were retrospectively reviewed and analyzed. According to receiving iron chelation or not, they were divided into treatment group (n=21, oral administration of deferasirox) and control group (n=17, no iron chelation). The changes of hemoglobin (Hb) level, platelet (PLT) count, white blood cell (WBC) count and serum ferritin (SF) level were compared between the 2 groups, and the adverse reactions during administration were observed as well. Results At 2, 4 and 8 weeks after treatment, Hb level and PLT count in the treatment group were significantly improved from baseline as compared with the control group (P < 0.05), but the WBC count showed no significant difference between the 2 groups (P > 0.05). SF levels in the treatment group was decreased from baseline at 4 and 8 weeks, significantly lower than those of the control group [-867 (-1 918~ 477) vs 436 (-408~467) μg/L, P < 0.001;-1 243 (-2 784~364) vs 541 (-674~578) μg/L, P < 0.001]. None of the patients in the treatment group developed serious gastrointestinal symptoms or severe damage to liver and kidney functions. Conclusion Iron chelation therapy can effectively improve the hematopoiesis, with satisfactory safety, in the patients suffering from iron overload after allo-HSCT.
format	article
author	ZENG Cong CHEN Xu HUA Juan CHENG Tingting MA Xia XU Yajing
author_facet	ZENG Cong CHEN Xu HUA Juan CHENG Tingting MA Xia XU Yajing
author_sort	ZENG Cong
title	Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation
title_short	Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation
title_full	Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation
title_fullStr	Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation
title_full_unstemmed	Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation
title_sort	iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation
publisher	Editorial Office of Journal of Third Military Medical University
publishDate	2021
url	https://doaj.org/article/aff6134d7f3e4637b48cc93cef7c13a5
work_keys_str_mv	AT zengcong ironchelationtherapyimproveshematopoiesisinpatientswithhematologicalmalignancyafterhematopoieticstemcelltransplantation AT chenxu ironchelationtherapyimproveshematopoiesisinpatientswithhematologicalmalignancyafterhematopoieticstemcelltransplantation AT huajuan ironchelationtherapyimproveshematopoiesisinpatientswithhematologicalmalignancyafterhematopoieticstemcelltransplantation AT chengtingting ironchelationtherapyimproveshematopoiesisinpatientswithhematologicalmalignancyafterhematopoieticstemcelltransplantation AT maxia ironchelationtherapyimproveshematopoiesisinpatientswithhematologicalmalignancyafterhematopoieticstemcelltransplantation AT xuyajing ironchelationtherapyimproveshematopoiesisinpatientswithhematologicalmalignancyafterhematopoieticstemcelltransplantation
_version_	1718431252258750464

Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation

Ejemplares similares